bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease

bluebird bio (NASDAQ: BLUE) reported Q4 EPS of $0.38, $0.76 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $884.67 thousand.

LOVO-CEL

• BLA submission anticipated following response from FDA on analytical comparability data in the coming weeks.
• The Company continues to anticipate commercial launch in early 2024, if approved.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• NeOnc gets UAE approval for NEO100 brain cancer drug trials
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook